SCHEMBL23728637

SCHEMBL23728637

C=CCOCCOCCOCCOCCOCCOCCOCCOCCNC(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.47
HTR1A P08908 1/20 0.47
TDP1 Q9NUW8 1/20 0.45
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
GAA P10253 1/20 0.43
CA12 O43570 4/20 0.41
CA1 P00915 4/20 0.41
CA2 P00918 4/20 0.41
CA9 Q16790 4/20 0.41
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
IDO1 P14902 1/20 0.39
BCHE P06276 1/20 0.39
CNR2 P34972 1/20 0.39
EPHX1 P07099 1/20 0.38
EGFR P00533 1/20 0.36
ITK Q08881 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30980669 1.00 ADRB2 (0.47) ADRB2HTR1ATDP1MEN1KMT2A
SCHEMBL21106804 1.00 ADRB2 (0.47) ADRB2HTR1ATDP1MEN1KMT2A
SCHEMBL13114987 0.97 TDP1 (0.47) ADRB2HTR1ATDP1MEN1KMT2A
SCHEMBL25657888 0.89 ADRB2 (0.44) ADRB2HTR1ATDP1MEN1KMT2A
SCHEMBL8843547 0.88 TDP1 (0.53) ADRB2HTR1ATDP1MEN1KMT2A
SCHEMBL22276641 0.87 TDP1 (0.56) ADRB2HTR1ATDP1MEN1KMT2A
SCHEMBL22276648 0.87 TDP1 (0.56) ADRB2HTR1ATDP1MEN1KMT2A
SCHEMBL12885084 0.87 TDP1 (0.56) ADRB2HTR1ATDP1MEN1KMT2A
SCHEMBL27317790 0.86 TDP1 (0.55) ADRB2HTR1ATDP1MEN1KMT2A
SCHEMBL12079730 0.86 ADRB2 (0.43) ADRB2HTR1ATDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240050576-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2024-02-15 US disclosed
US-20230149550-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2023-05-18 US disclosed
US-20230149550-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2023-05-18 US disclosed
CN-115768765-A Methods and compounds for treating genetic diseases 设计治疗公司 2023-03-07 CN disclosed
EP-4100404-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. (US) 2022-12-14 EP disclosed
WO-2021158707-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. (US) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149550-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE DMPK, DTYMK, MYCBP ADRB2 4052/4885HTR1A 2436/4885TDP1 70/4885
US-20240050576-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE ZFX, GRN, F13B ADRB2 4464/4885HTR1A 1744/4885TDP1 258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.